Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Stock Information for Organogenesis Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025
Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results
Organogenesis Shares ReNu® Program Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.